Diarylacetylene hydrazide containing tyrosine kinase inhibitors

A compound of formula (I),

• or pharmaceutically acceptable salt thereof, wherein;
• ring P and ring Q are independently selected from an aryl ring having 6 to 14 carbon atoms, or a 5 to 14 membered heteroaryl ring containing one to four hetero atoms each independently selected from O, S and N, optionally substituted by one or more identical or different radicals R3, with a proviso that when ring Q is pyridyl then ring P is heteroaryl;
• R1 and R2 are independently selected from the group consisting of hydrogen, —C1-8-alkyl, —C2-10-alkenyl, —C2-12-alkynyl, —C3-12-cycloalkyl, —C4-12-cycloalkylalkyl, —C3-12-cycloalkenyl, aryl, heteroaryl, arylalkyl and a heteroarylalkyl radical, wherein the aryl ring contains 6 to 14 carbon atoms, and the heteroaryl ring contains 5 to 14 membered ring system with one to four hetero atoms each independently selected from O, S and N, and are optionally substituted by one or more identical or different radicals R3;
• X and Y are independently selected from the group consisting of C═O and;
• R3 is selected from the group consisting of halogen, —OH, —CN, —NO2, —N3, —C1-8-alkyl, —C3-12-cycloalkyl, —(C1-8-alkyl)-C3-12-cycloalkyl, -heterocycloalkyl containing 3 to 12 rings atoms having one or two hetero atoms each independently selected from O, S and N, —(C1-8-alkyl)-heterocycloalkyl containing 3 to 12 rings atoms having one or two hetero atoms each independently selected from O, S and N, —O—C1-8-alkyl, —O—C3-12-cycloalkyl, —O-aryl, —O-heteroaryl, —C1-8 alkyl-O—C1-8 alkyl, —O—C1-8 alkyl-O—C1-8 alkyl, —O—C1-8 alkyl-NH(C1-8 alkyl), —O—C1-8 alkyl-N(C1-8 alkyl)2, —O—C1-8 alkyl-(heteroaryl), —C(O)—C1-8 alkyl, —COOH, —C(O)NH2, —C(O)NH—C1-8 alkyl, —C(O)N(C1-8 alkyl)2, —C(O)O—C1-8 alkyl, —C1-8 haloalkyl, —C2-10 alkenyl, —C2-12 alkynyl, —OC(O)—NH2, —OC(O)—NH(C1-8 alkyl), —OC(O)—N(C1-8 alkyl)2, —NH2, —NH(C1-8 alkyl), —N(C1-8 alkyl)2, —NH—SO2—C1-8 alkyl, —N(C1-8 alkyl)-SO2—C1-8 alkyl, —NH—C(O)—(C1-8 alkyl), —N(C1-8 alkyl)-C(O)—(C1-8 alkyl), —NH—C(O)O—C1-8 alkyl, —N(C1-8 alkyl)-C(O)O—C1-8 alkyl, —NH—C(O)—NH2, —NH—C(O)—NH(C1-8 alkyl), —N(C1-8 alkyl)-C(O)—NH(C1-8 alkyl), —N(C1-8 alkyl)-C(O)—N(C1-8 alkyl)2, —NH—C(O)—NH—SO2—C1-8 alkyl, —N(C1-8 alkyl)-C(O)—NHSO2—C1-8 alkyl, —N(C1-8 alkyl)-C(O)—N(C1-8 alkyl)-SO2—C1-8 alkyl, —S—C1-8 alkyl, —S(O)—C1-8 alkyl, —SO2—C1-8 alkyl, —S-aryl, —S(O)-aryl, SO2-aryl, —SO2NH2, —SO2NH—(C1-8 alkyl), —SO2N(C1-8 alkyl)2;
• -aryl, —(C1-4-alkyl)-aryl, heteroaryl or —(C1-4-alkyl)-heteroaryl group, wherein the aryl ring contains 6 to 14 carbon atoms, and the heteroaryl ring contains 5 to 14 membered ring system with one to four hetero atoms each independently selected from O, S and N, wherein each of the aforementioned R3 groups may be optionally substituted with a single group selected from the group consisting of:
• C1-4-alkyl, C1-4-alkoxy, C1-4-haloalkyl, —OH, —COOH, —CN, —NO2, halo, —NH2 and —SO2NH2.